wb_incandescent Backtest


Regeneron Pharmaceuticals Inc. Common Stock

Official Company Name: Regeneron Pharmaceuticals, Inc.

Stock Symbol: REGN

Stock Market: NASDAQ Global Select - NASDAQ

Currency: United States dollar - USD

business Regeneron Pharmaceuticals, Inc. Company Profile

REGN Stock Price - 1 Year Price Evolution & Moving Averages

1 Year Return



Daily closing prices, with moving averages and volumes - United States dollar (USD)
Moving averages:

  • EMA20
  • SMA50
  • SMA200

Company Description

Regeneron Pharmaceuticals, Inc. is a biotechnology company dedicated to molecules signaling, and targeted antibody drugs. Thanks to its patented treatments and technologies, Regeneron provides remedies for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic diseases, infectious diseases, and rare diseases.

business Regeneron Pharmaceuticals, Inc. Company Profile

REGN Stock Data

Open $1,056.00
High $1,066.43
Low $1,052.81
Close $1,060.86
Volume 448,526
Previous Close $1,055.57
1-Day Change 5.29
1-Year Change 329.90
Average Daily Volume 483,555
52-Week High $1,100.05
52-Week Low $730.96

REGN Stock References



All information and data available on Disfold is NOT FINANCIAL ADVICE. Invest at your own risk!

Past performance is not a guarantee of future performance. Patterns tend to repeat themselves, but they don't necessarily have to.

Successful backtests on past data do not guarantee the future success of the strategy backtested, especially as backtest overfitting may occur: when the price of a stock may fit particularly well a given trading strategy over a given period, but not necessarily outside of that period. Besides, backtests do not account for exact market conditions and may yield significantly different results in real trading practice (fees, slippage...).

Furthermore, even though Disfold strives to provide the best and most accurate data, errors can occur in Disfold's systems, or in our data providers' systems.

Please conduct your own due diligence to verify insights.